TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04507711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 ul of palonosetron
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 ul of palonosetron
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 ul of palonosetron
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 ul of palonosetron
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
Study: NCT04057872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
Study: NCT01944800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Loading dose of 180 mg, followed by maintenance dose of 180 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg
Study: NCT03274830

Intervention type: DEVICE
Intervention: aneXys
Description: 150 patients with the aneXys cup
Study: NCT01306630

Intervention type: DRUG
Group type: OTHER
Intervention: tivozanib (AV-951) and capecitabine (Xeloda®)
Description: Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
Study: NCT01054586

Intervention type: DRUG
Intervention: Intervention A Standard dose
Description: HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
Study: NCT02395549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% (w/w) MTC896 Gel
Description: 1.5% (w/w) MTC896 Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control Gel
Study: NCT01054586

Intervention type: DRUG
Intervention: Intervention B Reduced Dose
Description: HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).

Intervention type: DRUG
Intervention: Intervention C
Description: HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.

Intervention type: DRUG
Intervention: Intervention D
Description: HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.

Intervention type: DRUG
Intervention: Intervention E
Description: HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
Study: NCT00594477

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study: NCT02280850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanxin Shutong Capsule
Description: 3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 3 capsules three times a day; Duration: 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitroglycerine
Description: Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.
Study: NCT02327299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FePP

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FePP + Stabilizer

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FeSO4

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bouillon fortified with FeSO4 + Stabilizer
Study: NCT01929057

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: 4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: 4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Approximately half a tube of blood will be drawn from all participants in the study

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Approximately half a tube of blood will be drawn from all participants in the study
Study: NCT01125332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indirect laryngoscopy in the flexible nasofibroscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect laryngoscopy in the flexible nasofibroscope
Study: NCT02613208

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered as per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per local clinical practice and local labeling.
Study: NCT02224235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity DES
Description: Resolute Integrity DES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: At the discretion of the investigator as to which DAPT is administered (per local practice)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: At the discretion of the investigator as to which DAPT is administered (per local practice)
Study: NCT03656965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 800 MG
Description: Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Description: Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Radiotherapy and chemotherapy
Description: Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
Study: NCT00237679

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Unstimulated
Description: No current is generated.
Study: NCT00770445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and insulin
Description: Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and metformin and insulin
Description: Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and insulin
Description: Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
Study: NCT03096041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auriculotherapy for analgesic use
Description: The ASP will be applied to specific pain points

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo auriculotherapy
Description: The ASP will be applied to placebo points (not specific to pain)
Study: NCT03712007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAMP therapy with MARPE expander
Description: Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAMP therapy with Hyrax expander
Description: Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
Study: NCT03458715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (Empagliflozin 25 MG)
Description: We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP4 inhibitor (Linagliptin 5 MG)
Description: We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
Study: NCT03679442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
Study: NCT01564056

Intervention type: DRUG
Group type: OTHER
Intervention: HORMONOTHERAPY
Description: Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Study: NCT02964260

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy drug
Description: Doxorubicin/Platinum agents

Intervention type: DRUG
Group type: OTHER
Intervention: Embolic agents
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Embolic agents
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneously
Description: 1-3 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequentially
Description: 1 month

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation
Description: Radiofrequency ablation/Microwave ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Radiofrequency ablation/Microwave ablation
Study: NCT02360982

Intervention type: BEHAVIORAL
Intervention: propofol and esmeron(rokuronyum)
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
Study: NCT03856944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR Toric
Description: ReSTOR Toric bilateral IOL implantation
Study: NCT04547322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR application group
Description: During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
Study: NCT01564056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEMOTHERAPY then HORMONOTHERAPY
Description: CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Study: NCT02446171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
Study: NCT02360982

Intervention type: BEHAVIORAL
Intervention: propofol and esmeron(rokuronyum)
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).

Intervention type: BEHAVIORAL
Intervention: marcaine and fentanyl
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).

Intervention type: BEHAVIORAL
Intervention: marcaine and fentanyl
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
Study: NCT02446171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
Study: NCT04641130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to birch pollen in EEC
Description: Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
Study: NCT00707161

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
Study: NCT02446171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg (10 mL oral solution)
Description: naloxegol 25 mg (10 mL oral solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg (10 mL oral solution)
Description: naloxegol 25 mg (10 mL oral solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg (10 mL oral solution)
Description: naloxegol 25 mg (10 mL oral solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg (10 mL oral solution)
Description: naloxegol 25 mg (10 mL oral solution)
Study: NCT00707161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
Study: NCT02446171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, given orally
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, given orally
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, given orally
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, given orally
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally
Study: NCT03712423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cripec Docetaxel
Description: 89 Zirconium Cripec Docetaxel PET
Study: NCT02648633

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Subjects will receive a single large dose of radiation to one or more lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
Study: NCT00669409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 10 mcg/kg IV
Study: NCT03543462

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: thoracic Drain Tube 24 Fr.
Description: Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
Study: NCT01406418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 2 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study: NCT00669409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 100 mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 200 mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 25 mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 50 mcg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04383119 (tanezumab)
Description: single dose of Placebo IV
Study: NCT02879045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elasticity Belly® oil
Description: We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
Study: NCT03502330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
Study: NCT02984072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: Topical menthol in aqueous cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous Cream
Description: placebo
Study: NCT01324518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 60mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 200mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ORM-12741
Description: Placebo twice a day